Skip to main content

Table 4 Cost-effectiveness results: ERG revisions to company base case

From: Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Description Nab-Pac + Gem vs. Gem Nab-Pac + Gem vs. Gem + Cap Nab-Pac + Gem vs. FOLFIRINOX
Company original base case £46,657 Dominated Dominated
Company updated base case £46,932 Dominated Dominated
ERG corrected company base case £47,011 Dominated Dominated
 R1) HRs for Gem + Cap vs. Gem £103,827
 R2) HRs for FOLFIRINOX vs. Gem £47,012 Dominated £3327
 R3) ERG drug-costing method £39,289 Dominated Dominated
 R4) TOT from CA046 trial £49,922 Dominated Dominated
 R5) Do not apply AE disutilities £46,994 Dominated Dominated
 R6) ERG OS £46,681 Dominated Dominated
 R7) ERG PFS £46,933 Dominated Dominated
ERG revised base case (R3, R4, R5, R6, R7) £41,250
ERG revised base case (R1, R3, R4, R5, R6, R7) £99,837
ERG revised base case (R2, R3, R4, R5, R6, R7) Dominated
  1. AE adverse event, ERG Evidence Review Group, FOLFIRINOX combination of oxaliplatin, irinotecan, leucovorin and fluorouracil, Gem gemcitabine, Gem + Cap gemcitabine in combination with capecitabine, HRs hazard ratios, Nab-Pac + Gem paclitaxel as albumin-bound nanoparticles in combination with gemcitabine, Nab-Pac + Gem paclitaxel as albumin-bound nanoparticles in combination with gemcitabine, PFS progression-free survival, OS overall survival, TOT time on treatment